Format

Send to

Choose Destination
Am J Surg. 2015 Sep;210(3):424-30. doi: 10.1016/j.amjsurg.2015.03.008. Epub 2015 May 12.

Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.

Author information

1
Department of Surgery and Oncology, University of Calgary, Room 1006 & 1023, North Tower, 1403-29 Street NW, Calgary, Alberta T2N 2T9, Canada. Electronic address: Jennifer.yk.lam@albertahealthservices.ca.
2
Department of Surgery and Oncology, University of Calgary, Room 1006 & 1023, North Tower, 1403-29 Street NW, Calgary, Alberta T2N 2T9, Canada; Department of Surgery, University of British Columbia, Diamond Health Care Centre, 5th Floor, 2775 Laurel Street, Vancouver, British Columbia V5Z 1M9, Canada.
3
Department of Surgery and Oncology, University of Calgary, Room 1006 & 1023, North Tower, 1403-29 Street NW, Calgary, Alberta T2N 2T9, Canada; Department of Surgery, University of Manitoba, GF441, 820 Sherbrook Street, Winnipeg, Manitoba, Canada R3A 1R9.
4
Department of Surgery and Oncology, University of Calgary, Room 1006 & 1023, North Tower, 1403-29 Street NW, Calgary, Alberta T2N 2T9, Canada.

Abstract

BACKGROUND:

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have improved survival for colorectal and high-grade appendiceal carcinomatosis. We compared the overall and recurrence-free survival (OS and RFS) of patients treated with HIPEC with mitomycin c and early postoperative intraperitoneal chemotherapy (EPIC) with fluorouracil versus HIPEC alone using oxaliplatin and simultaneous IV infusion of fluorouracil.

METHODS:

Ninety-three patients with colorectal or high-grade appendiceal carcinomatosis were treated with CRS and HIPEC + EPIC or HIPEC alone. OS and RFS were analyzed using Kaplan-Meier curves and log-rank testing.

RESULTS:

Survival did not differ between HIPEC regimens. The 3-year OS and RFS rates were 50% and 21% for HIPEC + EPIC and 46% and 6% for HIPEC alone (P = .72 and P = .89, respectively). HIPEC + EPIC patients experienced more grade III/IV complications (43.2% vs 19.6%, P = .01).

CONCLUSIONS:

There was no difference in OS and RFS between colorectal and high-grade appendiceal adenocarcinoma patients treated with CRS and HIPEC + EPIC versus HIPEC alone. However, HIPEC + EPIC patients suffered greater morbidity, making HIPEC alone the preferable regimen.

KEYWORDS:

Colorectal cancer; Cytoreduction; HIPEC; Peritoneal carcinomatosis; Survival

PMID:
26051744
DOI:
10.1016/j.amjsurg.2015.03.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center